에 대한 최신 뉴스 Outset Medical (NASDAQ:OM) 주식

Outset Medical

Outset Medical Inc is a medical technology company. It has developed a machine, Tablo, which reduces the cost and complexity of dialysis. Tablo provides Renal Replacement Therapy in Hospitals, Chronic Care in Dialysis Clinics and Home Dialysis.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

BLBD

USFD

목요일 오전 (현지 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:

목요일 주목해야 할 주식: 일라이 릴리, US 푸즈, 블루 버드 그리고 종목

Outset Medical Inc

MANTRA DAO

Grupo Aeroportuario del Centro Norte S.A.B. de C.V. - American Depositary Shares each representing 8 Series B shares

Grupo Aeroportuario del Centro Norte SAB de CV

Omagine Inc

Origin Protocol - United States Dollar

Omnicom Group Inc

Old Market Capital Corporation - Common Stock

Old Market Capital Corp

Omnicell Inc

ORMAND INDUSTRIES INC by Ormand Industries, Inc.

Ormand Inds Inc

Omeros Corp

Odyssey Marine Exploration, Inc. - Common Stock

Odyssey Marine Exploration Inc

OneMain Holdings Inc

Invesco Exchange-Traded Self-Indexed Fund Trust Invesco Russell 1000 Dynamic Multifactor ETF

Invesco Exchange-Traded Self-Indexed Fund Trust Invesco Russell 2000 Dynamic Multifactor ETF

OmiseGO - United States Dollar

Omega Therapeutics Inc

OMAI GOLD MINES CORP by OMAI GOLD MINES CORP.

Omai Gold Mines Corp

OMEGA PAC RES INC by Omega Pacific Resources Inc.

Omega Pacific Resources Inc

Ohmyhome Ltd

Omni Health Inc

OM HOLDINGS INTL INC by OM Holdings International, Inc.

Om Holdings International Inc

OM Holdings Ltd

Owens & Minor Inc

Singular Genomics Systems, Inc. - Common Stock

Singular Genomics Systems Inc

Omid Holdings Inc

oOh media Ltd

OMNIMMUNE HOLDINGS INC by Omnimmune Holdings, Inc.

Omnimmune Holdings Inc

OMINECA MINING & MTLS ORD by Omineca Mining & Metals Ltd.

Omineca Mining and Metals Ltd

Omni Network - United States Dollar

Omphalos Corp

OMNIQ Corp

OMRON Corp

Orthometrix Inc

OMNITEK ENGINEERING CORP by Omnitek Engineering Corp.

OmniTek Engineering Corp

Omni Ventures Inc

OMV AG

Omnia Wellness Inc

Osisko Metals Inc

A new report has revealed a startling trend in the cryptocurrency market: 76% of influencers on X (formerly Twitter( promoting meme coins are endorsing tokens that eventually lose <a href="https://www.benzinga.com/markets/cryptocurrency/24/02/37184038/crypto-trader-sinks-88-900-on-drake-affiliated-wynn-i-will-never-forgive-you-for-making-me">nearly all their value</a>.
What Happened: The <a href="https://coinwire.com/76-percent-twitter-influencers-promote-dead-memecoins-study/">study</a>, by CoinWire, analyzed 1,567 meme coins promoted by 377 influencers, uncovering that two out of three tokens they promoted are now classified as "dead."
The report's findings are particularly concerning for retail investors drawn to the hype surrounding popular meme coins like Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>). 
While established tokens such as DOGE and SHIB have maintained significant market presence and liquidity, many of the promoted meme coins fail to replicate this success. 
Instead, they follow a pattern of rapid value decline, with 86% losing 90% of their value within three months of promotion.
Even the allure of potential 10x returns—often the centerpiece of influencer hype—proved elusive, with only 3% of promoted tokens achieving such gains. 
Larger influencers, those with over 200,000 followers, fared worse, delivering 89% negative returns on promoted tokens within three months, compared to smaller influencers who sometimes achieved positive results.
"Influencers benefit financially from these promotions, with average earnings of $399 per tweet," the report states. "However, the data shows that these endorsements frequently lead to significant losses for their followers."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42166673/drug-cartels-use-tether-and-bitcoin-to-launder-millions-court-documents-reveal">Drug Cartels Use Tether And Bitcoin To Launder Millions, Court Documents Reveal</a>
Why It Matters: Speaking with Benzinga, Eric Chen, CEO and co-founder of Injective Labs said that influencers in crypto represent a broad spectrum of individuals and strategies. 
While some may chase momentum by promoting volatile or speculative tokens, others focus on more nuanced, qualitative insights, Chen said. 
He cautioned against oversimplifying the role of influencers, noting that token performance depends on a variety of factors, including market sentiment, retail investor activity, and decisions by larger players like whales.
"While there are undoubtedly some bad actors in the space, it's unfair to generalize the actions of a few as representative of the entire group. Market direction is driven by a wide array of participants, not just influencers," Chen added.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42165734/bitcoin-etfs-registered-record-312-billion-net-inflows-last-week">Bitcoin ETFs Registered Record $3.12 Billion Net Inflows Last Week</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$SHIB

Don't Get Fooled By The Success Of Dogecoin, Shiba Inu: 76% Of X (Twitter) Influencers Promote Dead Meme Coins, Study Reveals

B. Riley Securities analyst Hal Goetsch maintains Priority Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) with a Buy and raises the price target from $13 to $16.

Price Target

Analyst Ratings

PRTH

B. Riley Securities Maintains Buy on Priority Tech Holdings, Raises Price Target to $16

A <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/topic/dea-cannabis&amp;ved=2ahUKEwi-55vk7veJAxX8IbkGHctZFHAQFnoECBkQAQ&amp;usg=AOvVaw2exrY_OTgOJ9N-asMwoMUl">DEA</a> administrative law judge has denied MedPharm's motion to participate in the December 2 marijuana rescheduling hearing, deferring to DEA Administrator Anne Milgram's authority. 
MedPharm, a DEA-registered research firm, criticized the exclusion of marijuana researchers and the inclusion of prohibitionist organizations, calling the process biased.
<h3 class="wp-block-heading">MedPharm&#8217;s Motion And Criticism</h3>
MedPharm filed a motion to intervene after being excluded from the witness list, arguing the fact that no DEA-licensed marijuana researchers were included.
"The deck appears to be stacked against those in favor" of rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA), MedPharm noted.
It also alleged that the witness list, which included the anti-cannabis prohibitionist group <a href="https://www.benzinga.com/markets/cannabis/24/05/38733313/anti-cannabis-group-raises-money-to-scuttle-dea-rescheduling-effort">Smart Approaches to Marijuana</a> (SAM), undermines the legitimacy of the process, describing the decision as an attempt to &#8220;thwart a legitimate process,&#8221; as <a href="https://www.marijuanamoment.net/dea-judge-denies-agency-registered-drug-companys-request-to-join-marijuana-rescheduling-hearing/">reported</a> Marijuana Moment.
Read Also: <a href="https://www.benzinga.com/24/11/42144540/dea-slammed-over-unlawful-talks-with-cannabis-opponents-the-plot-thickens">DEA Slammed For Unlawful Talks With Cannabis Opponents &#8211; The Plot Thickens</a>
Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">Judge Mulrooney's Decision</h3>
DEA Administrative Law Judge John Mulrooney denied MedPharm's motion, citing statutory limits on his authority. 
"The Administrator exercised her discretion to fix the number of participants," Mulrooney said, adding that expanding the list would exceed his role under the Administrative Procedures Act.
Mulrooney acknowledged the value of wider input but noted that the DEA prioritizes participants who can demonstrate adverse impacts from the proposed policy change, which becomes apparent by viewing the <a href="https://www.benzinga.com/markets/cannabis/24/11/41726679/village-farms-is-only-cannabis-operator-selected-to-represent-weed-industry-at-dea-rescheduling-">biased list</a>.
The exclusion of key scientific voices has <a href="https://www.benzinga.com/markets/cannabis/24/11/41726679/village-farms-is-only-cannabis-operator-selected-to-represent-weed-industry-at-dea-rescheduling-">raised concerns</a> about the process's fairness, particularly as the Department of Health and Human Services (HHS) and the DEA&#8217;s Office of Legal Counsel support rescheduling.
The upcoming hearing will allow cross-examination of witnesses from both sides, but critics warn the imbalance could skew outcomes. Mulrooney is leading another case where the DEA is accused of engaging in <a href="https://www.benzinga.com/24/11/42144540/dea-slammed-over-unlawful-talks-with-cannabis-opponents-the-plot-thickens">unlawful conversations</a> with anti-cannabis groups ahead of the December 2 hearing.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/11/42093641/dea-is-compromised-doj-should-replace-it-in-cannabis-rescheduling-claims-joint-motion">DEA Is Compromised, DOJ Should Replace It In Cannabis Rescheduling, Claims Joint Motion</a></li>
</ul>
Cover: AI generated image

Cannabis

Government

Politics

DEA Judge Blocks Researcher's Motion In Cannabis Rescheduling Case,

<a href="https://www.reuters.com/legal/government/us-justice-dept-questions-scope-realtor-groups-418-mln-settlement-2024-11-25/" title="https://www.reuters.com/legal/government/us-justice-dept-questions-scope-realtor-groups-418-mln-settlement-2024-11-25/">https://www.reuters.com/legal/government/us-justice-dept-questions-scope-realtor-groups-418-mln-settlement-2024-11-25/</a>

Legal

RMAX

'The U.S. Justice Department's Antitrust Division Warned A Federal Judge On Sunday That Part Of A Proposed $418M Settlement In A Class Action Over Home Sales Commissions Could Limit How Real Estate Brokers Compete; The Settlement With The National Association Of Realtors Would End The Practice Of Forcing Home Sellers To Pay A Commission To A Buyer's Agent In Order To List Their Homes For Sale' - Reuters

Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) stock is trading higher on Monday following a report indicating that the company is close to securing a $8 billion <a href="https://www.benzinga.com//node/42157390">grant</a>. 
What To Know: According to CNBC which <a href="https://www.cnbc.com/2024/11/25/intel-close-to-8-billion-chips-act-grant-source.html">cited</a> people familiar with the matter, the CHIPS Act Office and Intel are close to finalizing an approximately $8 billion dollar grant. 
If awarded, the $8 billion is set to fund Intel's factory building efforts. The award is expected to be finalized by the CHIPS Act Office, which operates under the U.S. Commerce Department, within the next few weeks.
The New York Times, citing people with familiar with the matter, <a href="https://www.nytimes.com/2024/11/24/business/washington-curtails-intel-grant.html">reported</a> that the government has decided to reduce the grant from $8.5 billion to about $8 billion after the company delayed certain investments and continues to face other business struggles.
Specifically, the reduction takes into account the fact that Intel decided to delay its planned investments in chip facilities in Ohio. The company intends to complete the project by the end of the decade instead of its original 2025 target.
Furthermore, Intel has struggled to match the technological capabilities of competitors like Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) and recently reported its largest quarterly loss. The government&#8217;s choice to reduce the grant also takes into account a $3 billion contract to manufacture chips for the U.S. military.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42154900/crypto-expert-who-called-2022-market-crash-warns-about-bitcoin">Crypto Expert Who Called 2022 Market Crash Warns About Bitcoin</a>
INTC Price Action: At the time of pubication, Intel stock is trading 2.84% higher at $25.20, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Unsplash

Movers

INTC

What's Going On With Intel Shares Monday?

B. Riley Securities analyst Kalpit Patel maintains PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) with a Buy and lowers the price target from $9 to $7.

PDSB

B. Riley Securities Maintains Buy on PDS Biotechnology, Lowers Price Target to $7

Ben &amp; Jerry's and Unilever are no longer the perfect match they seemed to be 20 years ago. In 2000, Unilever bought the progressive ice cream company, hoping to bottle some of its feel-good vibes and sprinkle them across its corporate culture. For a while, it worked. Ben &amp; Jerry's became a billion-dollar brand, growing while still standing for things like same-sex marriage, climate action and even Occupy Wall Street.
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest TODAY for just $0.26/share with a $1000 minimum.</a></li>
</ul>
But times have changed. Last week, <a href="https://www.benzinga.com/news/global/24/11/41984983/ben-jerrys-sues-parent-company-unilever-over-alleged-gaza-protest-censorship">Ben &amp; Jerry's sued Unilever</a>, accusing the parent company of breaking an agreement by blocking its support for Palestinian rights. Ben &amp; Jerry's claims Unilever threatened to "dismantle" its independent board and sue board members if the subsidiary issued a statement calling for "peace and a permanent and immediate ceasefire" in the Middle East. This is according to a Nov. 13 complaint filed in federal court in New York. The suit also alleges Peter ter Kulve, president of Unilever's ice cream business and Jeff Eglash, Unilever's global head of litigation, warned Ben &amp; Jerry's employees of "professional reprisals" if they pushed for a ceasefire.
Unilever responded, saying its "heart goes out to all the victims of the tragic events in the Middle East." But it firmly rejected the claims made by Ben &amp; Jerry's social mission board. "We will defend our case very strongly," a spokesperson said in comments emailed to ESG Dive on Tuesday.
This rift goes back to 2021, when Ben &amp; Jerry's decided to stop selling in the Israeli-occupied West Bank, stating it was "inconsistent with our values."
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
For Unilever, this is about more than just ice cream. It's about dollars and cents. Gaza and its implications for<a href="https://www.benzinga.com/news/earnings/24/07/39959838/unilever-boasts-improved-profitability-power-brands-led-gross-margin-expansion-ceo-says"> financial performance</a> are business issues for them. But Ben &amp; Jerry's sees it differently, viewing it as a moral stand. And that's where things get messy.
The clash isn't unique to these two brands. "Across corporate America, the calculus for companies has shifted wildly when it comes to speaking out and taking a stand," wrote columnist Beth Kowlitt of Bloomberg. "No topic today is apolitical, no issue uncontroversial." Supporting social or environmental causes comes with risks – boycotts, backlash and even falling profits. Brands like Bud Light, Disney and Target have learned the hard way that speaking out can cost.
Unilever used to focus heavily on brands with purpose. Vaseline helped Syrian refugees, Hellmann's fought food waste and Ben &amp; Jerry's was the crown jewel, the gold standard for doing good. But under pressure from activist investors and flagging results, Unilever started scaling back. Plastic reduction goals were cut and living wage commitments softened.
See Also: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
Meanwhile, Ben &amp; Jerry's stuck to its guns. When Unilever took over, its independent board was created to protect its social mission. That division – board for social causes, Unilever for the business – used to work. Not anymore. The line between mission and money has blurred and Unilever is learning this the hard way.
This isn't just about ice cream. It's about the end of an era. Companies once paid a premium for brands like Ben &amp; Jerry's, hoping their values would rub off. Coca-Cola bought Odwalla, PepsiCo picked up Naked Juice and Colgate snagged Tom's of Maine. But the shine of those "halo brands" has dimmed. Odwalla and Honest Tea are gone. Naked Juice was sold off.
Unilever plans to spin off or sell Ben &amp; Jerry's and its ice cream business. But will buyers see the brand's values as an asset or a liability? That's the billion-dollar question.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
</ul>

Startups

Ben & Jerry's And Unilever Clash Over Gaza As Social Stances Threaten A $1 Billion Brand

In the current session, the stock is trading at $134.25, after a 6.19% increase. Over the past month, e.l.f. Beauty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) stock increased by 18.17%, and in the past year, by 13.25%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732553107_0.png" alt="Past Year Chart" />

<h3>Evaluating e.l.f. Beauty P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
e.l.f. Beauty has a better P/E ratio of 68.34 than the aggregate P/E ratio of 44.3 of the Personal Products industry. Ideally, one might believe that e.l.f. Beauty Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732553107_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: e.l.f. Beauty

RBC Capital analyst Irene Nattel maintains Dollarama (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DOL#TSX">DOL</a>) with a Outperform and raises the price target from C$147 to C$160.

TSX:DOL

RBC Capital Maintains Outperform on Dollarama, Raises Price Target to C$160

B. Riley Securities analyst Josh Nichols maintains Ooma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) with a Buy and raises the price target from $14.5 to $15.5.

OOMA

B. Riley Securities Maintains Buy on Ooma, Raises Price Target to $15.5

Rumors

CRNT

Watching Ceragon Networks; Traders Circulate Stock Picked In Louis G. Navellier's Newsletter

Kohl&#8217;s Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) shares are trading higher by 5.6% to $17.99 Monday morning. The company is set to report third-quarter results Tuesday <a href="https://www.benzinga.com/quote/JWN/earnings">before the market open</a>.
What Happened: Kohl's heads into its third-quarter earnings release with a focus on improving operational efficiency and navigating continued sales pressure. In the second quarter, <a href="https://www.benzinga.com/news/earnings/24/08/40599429/kohls-q2-earnings-profit-beat-inventory-decline-margin-growth-and-more">net sales declined by 4.2% year-over-year</a> to $3.525 billion, with comparable sales down 5.1%. 
Despite these challenges, the company exceeded EPS expectations, reporting 59 cents versus the 44 cent consensus, supported by a 59-basis-point expansion in gross margin to 39.6%.
Operational improvements were evident as SG&amp;A expenses declined 4.2% year-over-year, contributing to a 26-basis-point increase in operating margin to 4.4%. Inventory management was a highlight, with a 9% year-over-year reduction in inventory, aligning with the company's efficiency goals.
<a href="https://www.benzinga.com/news/global/24/11/42156160/palantir-price-target-raised-to-75-by-dan-ives-amid-288-ytd-surge-analyst-calls-2025-a-primetime-year-for-ai">Read Also: Palantir Price Target Raised To $75 By Dan Ives Amid 288% YTD Surge</a>
For Q3, attention will likely focus on Kohl's ability to stabilize sales amidst macroeconomic headwinds and discretionary spending pressures, which impacted second-quarter performance. 
Key growth areas, including the Sephora partnership and categories like home decor and gifting, will be critical drivers. The recent partnership with Babies "R" Us may also begin contributing incremental gains.
Kohl's raised its FY24 EPS outlook to $1.75–$2.25, reflecting confidence in margin expansion, despite revised guidance for FY24 sales and comparable sales declines of 4–6% and 3–5%, respectively. Investors will look for evidence in third-quarter results that Kohl's is successfully executing its strategies to balance cost controls with growth investments.
Read Also: <a href="https://www.benzinga.com/general/biotech/24/11/42164927/cassava-sciences-controversial-alzheimers-drug-fails-to-hit-primary-goal-in-pivotal-study-halts-late-stage-studies">Cassava Sciences Alzheimer&#8217;s Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies</a>
<h2 class="wp-block-heading">How To Buy KSS Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Kohl&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, KSS has a 52-week high of $29.60 and a 52-week low of $16.12.

What's Going On With Kohl's (KSS) Stock?

WIIM

KODK

Eastman Kodak shares are trading higher after the company announced its income plan trust sold $764.4 million in illiquid assets to Mastercard Foundation for $550.6 million in cash.

Ethereum Classic (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/etc/usd">ETC</a>) has surged 60% to $31.17 over the past month, drawing attention in a crypto market increasingly driven by institutional interest and renewed enthusiasm for blockchain technologies. This rise aligns with a record <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42165734/bitcoin-etfs-registered-record-312-billion-net-inflows-last-week">$3.13 billion inflow</a> into digital asset investment products last week, as reported by CoinShares.
What To Know: Ethereum Classic is the original Ethereum blockchain, preserved after a contentious 2016 split following the DAO hack. While Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) adopted a new chain to reverse the effects of the hack, Ethereum Classic retained the unaltered blockchain.
ETC has carved out a niche as a decentralized smart contract platform, appealing to purists and developers who value its fixed monetary policy and proof-of-work consensus mechanism.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42161443/dogecoin-is-harder-money-than-bitcoin-says-raoul-pal-heres-what-the-numbers-say">Dogecoin Is &#8216;Harder Money&#8217; Than Bitcoin, Says Raoul Pal: Here&#8217;s What The Numbers Say</a>
Bitcoin ETFs accounted for $3.12 billion of the record inflows last week, fueling optimism across the digital asset ecosystem. Altcoins like Ethereum Classic benefited from the trickle-down effect as investors sought alternatives that offered potential for high returns.
Additionally, Ethereum Classic may be gaining traction as a proof-of-work alternative to Ethereum, which transitioned to a proof-of-stake model in 2022. ETC miners displaced by Ethereum's shift could find a home on Ethereum Classic's network, further enhancing its security and utility.
While the record inflows into Bitcoin-dominated headlines, Ethereum Classic's outsized gains highlight the growing interest in assets beyond Bitcoin and Ethereum.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42163156/why-bitcoins-rally-is-stalling-below-100000">Why Bitcoin&#8217;s Rally Is Stalling Below $100,000</a>

$ETC

$ETH

Ethereum Classic Surges 60% In A Month: What's Driving the Rally?

Guggenheim analyst John Heinbockel maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Buy and raises the price target from $61 to $63.

Guggenheim Maintains Buy on Kroger, Raises Price Target to $63

POET Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) shares are trading higher. The company on Monday announced plans to expand its capacity to meet <a href="https://www.benzinga.com/pressreleases/24/11/g42160002/poet-expands-capacity-to-meet-ai-infrastructure-demand">AI infrastructure demand</a>. 
What Happened: Poet announced plans to expand its optical engine production capacity in Malaysia. The company signed a binding Memorandum of Understanding with Quanzhou Sanan Optical Communication Technology (SAIC). Under the terms, SAIC will transfer to Poet its&nbsp;24.8%&nbsp;stake in the joint venture Super Photonics Xiamen, making Super Photonics a wholly owned subsidiary of Poet.
With control of Super Photonics Xiamen, Poet will gain the flexibility to implement its &#8220;China Plus One&#8221; strategy to locate its wafer-scale assembly operations outside of China.
Poet also said its been negotiating with several contract manufacturers in Malaysia to become the focal point for the company&#8217;s wafer-scale assembly of optical engines. Poet expects to sign an agreement this month and to begin operations by the end of the year. 
See Also: <a href="https://www.benzinga.com/news/global/24/11/42156160/palantir-price-target-raised-to-75-by-dan-ives-amid-288-ytd-surge-analyst-calls-2025-a-primetime-year-for-ai">Palantir Price Target Raised To $75 By Dan Ives Amid 288% YTD Surge: Analyst Calls 2025 A &#8216;Primetime&#8217; Year For AI</a>
&#8220;The addition of wafer-scale equipment to our assembly and test operations will significantly expand our production capacity to cover the projected needs of our customers for 800G optical engines being sold to AI networks through 2026,&#8221; said Suresh Venkatesan, chairman and CEO of Poet. 
&#8220;We can now project an assembly and test capacity exceeding one million optical engines per year, all dedicated to the 800G and higher speed transceivers required for AI clusters.&#8221;
Poet noted that definitive agreements related to the deal are expected to be signed by the end of November. 
POET Price Action: <a href="http://benzinga.com/quote/poet">Poet shares</a> were up 5.49% at $4.23 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Global

POET

What's Going On With POET Technologies Stock Monday?

Dollar Gen's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) short percent of float has risen 7.67% since its last report. The company recently reported that it has 6.55 million shares sold short, which is 3.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.69 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dollar Gen Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732552221_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dollar Gen has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Dollar Gen's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dollar Gen's peer group average for short interest as a percentage of float is 3.51%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Dollar Gen's Recent Short Interest

Unity Software's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) short percent of float has fallen 5.04% since its last report. The company recently reported that it has 24.40 million shares sold short, which is 6.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.33 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Unity Software Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732552215_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Unity Software has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Unity Software's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Unity Software's peer group average for short interest as a percentage of float is 6.78%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(U) - Analyzing Unity Software's Short Interest

CenterPoint Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>) short percent of float has fallen 5.82% since its last report. The company recently reported that it has 18.19 million shares sold short, which is 3.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.61 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>CenterPoint Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732552210_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CenterPoint Energy has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing CenterPoint Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, CenterPoint Energy's peer group average for short interest as a percentage of float is 2.47%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(CNP) - Analyzing CenterPoint Energy's Short Interest

Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) showcased a groundbreaking generative AI <a target="_blank" href="https://blogs.nvidia.com/blog/fugatto-gen-ai-sound-model/" rel="noreferrer noopener">model </a>named Fugatto. This model is designed as a versatile tool for creating and modifying sounds using text and audio prompts. Fugatto can generate and transform a mix of music, voices, and soundscapes, offering unprecedented capabilities to musicians, developers, and content creators.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/11/42139806/echostar-shares-sink-as-directv-terminates-acquisition-agreement" rel="noreferrer noopener">EchoStar Shares Sink As DirecTV Terminates Acquisition Agreement</a>
Fugatto, short for Foundational Generative Audio Transformer Opus 1, supports multiple tasks, such as generating new music, altering accents or emotions in voices, and crafting entirely novel soundscapes. These features mark a significant leap in audio AI innovation.
Fugatto empowers users to create audio that combines various instructions and prompts. For example, it can produce a trumpet sound mimicking a barking dog or generate a voice with a specific accent and tone.
Beyond music, Fugatto opens possibilities for advertising, education, and gaming. Advertisers can adjust campaign voiceovers for regional audiences, while educators can personalize content with voices familiar to learners. Game developers can modify audio assets or generate them dynamically based on gameplay.
Fugatto, powered by a 2.5-billion-parameter generative transformer, was trained on Nvidia DGX systems with 32 H100 Tensor Core GPUs. Its development involved a diverse team spanning several countries, which enhanced its multilingual and multi-accent capabilities. The model&#8217;s training relied on millions of audio samples, carefully curated to enable complex and diverse tasks.
Fugatto&#8217;s debut signifies a milestone in generative AI, promising to reshape how professionals interact with sound.
The model enables users to combine attributes like accent, tone, and emotion into one cohesive sound. For instance, it can create a dynamic soundscape transitioning from a thunderstorm to a tranquil dawn.
Nvidia stock surged 186% year-to-date.
Last week, Nvidia reported a <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/42099904/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full-steam" rel="noreferrer noopener">third-quarter revenue</a> of $35.1 billion, up 94%, beating the consensus estimate of $33.12 billion.
The company reported EPS of 81 cents, which beat the Street consensus estimate of 75 cents. Nvidia expects fourth-quarter revenue to be $37.5 billion plus or minus 2%.
Analysts highlighted Nvidia&#8217;s leadership in AI and data center technologies, with robust demand for its Blackwell and Hopper <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42119226/nvidia-analysts-see-stock-best-positioned-in-ai-not-worried-about-guidance-all-systems-go-for-blackwell-ramp" rel="noreferrer noopener">product lines driving growth through 2025.</a>
Investors can gain exposure to Nvidia through ProShares Ultra Semiconductors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USD#NYSE">USD</a>) and EA Series Trust Strive U.S. Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOC#NYSE">SHOC</a>).
Price Action: NVDA stock is down 2.7% at $138.12 at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42137930/boeing-secures-238-billion-deal-for-advanced-kc-46a-tankers" target="_blank" rel="noreferrer noopener">Boeing Secures $2.38 Billion US Air Force Deal for Advanced KC-46A Tankers</a></li>
</ul>
Photo via Shutterstock.

Equities

Tech

General

NVDA

EA Series Trust Strive U.S. Semiconductor ETF

SHOC

Nvidia Unveils Fugatto: AI Tool That Transforms Sound Creation For Music, Ads, And Gaming

Outset Medical (OM) has shared an update. Jim Hinrichs resigned from his positions on the Board and as Audit Committee Chair of Outset Medical, Inc...

Outset Medical Announces Board and Committee Leadership Changes

THE LAWSUIT: A class action securities lawsuit was filed against Outset Medical, Inc. (OM) that seeks to recover losses of Outset Medical sharehold...

Class Action Filed Against Outset Medical, Inc. (OM) Seeking Recovery for Investors – Contact Levi & Korsinsky LLP

In a report released on October 8, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Outset Medical (OM – Research Report), with a p...

RBC Capital Remains a Hold on Outset Medical (OM)

Warning: OM is at high risk of performing badly

A class action lawsuit was filed against Outset Medical ($OM) by Levi & Korsinsky on August 29, 2024. The plaintiffs (shareholders) alleged that th...

Class Action Lawsuit Against Outset Medical (NASDAQ:OM)

Medical Technology and Digital Health Analyst Thibault holds a virtual meeting with CEO Trigg and CFO Ahmed on November 12 hosted by BTIG. Publishe...

Outset Medical management to meet virtually with BTIG

Outset Medical Non-GAAP EPS of -$0.39 beats by $0.03, revenue of $28.7M beats by $1.8M

TD Cowen analyst Josh Jennings maintained a Buy rating on Outset Medical (OM – Research Report) yesterday and set a price target of $3.00. Josh Jen...

Outset Medical's Strong Q3 Performance and Strategic Expansion Justifies Buy Rating

Outset Medical, Inc. ( ($OM) ) has released its Q3 earnings. Here is a breakdown of the information Outset Medical, Inc. presented to its investors...

Outset Medical, Inc. Announces Solid Q3 2024 Results

Analyst Marie Thibault of BTIG maintained a Buy rating on Outset Medical (OM – Research Report), with a price target of $4.00. Marie Thibault has g...

Outset Medical's Promising Turnaround: A Buy Rating Backed by Strong Revenue and Strategic Focus

Press Releases

New Research Highlights Improvements in Quality of Life and Caregiver Experience for Home Hemodialysis Patients Using Tablo

Outset Medical, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. Oct. 28, 2024 Deadline to file Lead Plaintiff Motion

SHAREHOLDER ALERT: Holzer & Holzer, LLC Reminds Investors of the October 28, 2024 Lead Plaintiff Deadline in Class Action Lawsuits Filed on Behalf of Verve Therapeutics, Inc. (VERV), Sage Therapeutics, Inc. (SAGE), and Outset Medical, Inc. (OM) Shareholders

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Outset Medical, Inc. (OM)

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Outset Medical, Inc. - OM

Penny Stocks

OM Investors Have Opportunity to Lead Outset Medical, Inc. Securities Fraud Lawsuit

OM DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Outset Medical, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action – OM

Outset Medical, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - OM

Comments

Outset Medical

뉴스

에 대한 최신 뉴스 Outset Medical (NASDAQ:OM) 주식

목요일, 8월 08, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌